Nanopharm-logo-with-signature-Pantone (1)
Close this search box.

15 Nov 2014

Structural Dynamics of Fluticasone Propionate Processing


This comprehensive research study delves into the structural relaxation of micronized Fluticasone Propionate (FP) under various lagering conditions and its subsequent influence on the aerodynamic particle size distribution (APSD) of binary and tertiary carrier-based dry powder inhaler (DPI) formulations. The study meticulously investigates the changes in physicochemical, surface interfacial properties, and amorphous disorder levels of FP samples under different conditions. The findings suggest that environmental conditions during the lagering of FP can significantly impact its physicochemical and interfacial properties, thereby influencing the performance of binary and tertiary carrier-based dry powder inhaler formulations. This research provides valuable insights and a deeper understanding of the process-induced structural disorder, particle adhesion, and mechanical activation, which are crucial in the pharmaceutical industry.

Related Posts


Nanopharm Announces Exclusive Collaboration With Fluidda To Accelerate Regulatory Pathway For OINDP Using SmartTrack

Crystal Lake, Illinois, September 22, 2022 – Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE: ATR) in 2019, as part of the company’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.

Read More »